Pazopanib, Free Base (GW-786034, Armala, Votrient, CAS 444731-52-6), >99%

LC Laboratories' Product Number P-6706 - Pazopanib, Free Base (GW-786034, Armala, Votrient, CAS 444731-52-6), >99% - for research use only. Pazopanib is an oral, second-generation, potent and selective multi-targeted tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR), platelet-derived growth factor receptor and c-kit, key proteins responsible for tumor growth and angiogenesis. Pazopanib showed good potency against all of the human VEGFRs and some related tyrosine receptor kinases in vitro, and demonstrated antitumor activity against renal cell carcinoma (RCC), and breast, lung, and other related cancers. Preclinical evaluation has demonstrated excellent anti-tumor and anti-angiogenic activity. A Phase II clinical trial of pazopanib in untreated or cytokine/bevacizumab pretreated renal cell carcinoma has revealed promising activity with a favorable toxicity profile. Orally administered Pazopanib has good bioavailability to the retina/choroid and strongly suppresses choroidal neovascularization (CNV) in a dose-dependent manner in mice. Pazopanib inhibits in vivo tumor cell growth in a mouse xenograft model of human multiple myeloma (MM) associated with increased MM cell apoptosis, prolonged survival, and decreased angiogenesis. Pazopanib is the active ingredient in the drug product sold under the trade names Armala® and Votrient®. This drug is currently approved in at least one country for use in patients with advanced renal cell carcinoma (RCC) and for use in patients with advanced soft tissue sarcoma (STS) who have received prior chemotherapy. THE PAZOPANIB, FREE BASE RESEARCH COMPOUND SOLD BY LC LABORATORIES IS NOT ARMALA® NOR VOTRIENT®, AND IS NOT FOR HUMAN USE.

• Supplier: LC Laboratories
• Product #: P-6706
• Sku #: P-6706_200mg